A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03202940

Recruitment Status : Active, not recruiting

First Posted : June 29, 2017

Last Update Posted : April 23, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Genentech, Inc.

Information provided by (Responsible Party):

Ibiayi Dagogo-Jack, M.D., Massachusetts General Hospital

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	January 1, 2025
Estimated Study Completion Date :	January 1, 2027

To Top